Observational study of IDH-mutant gliomas in Brazil
This study collects information about people in Brazil who have a type of brain tumor called an IDH-mutant glioma, diagnosed in 2021 or after. It aims to learn more about the characteristics and outcomes of these tumors, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years old or older.
- You must have a confirmed diagnosis of a glioma (a type of brain tumor) from 2021 or later.
- Your tumor must have a confirmed IDH mutation (a specific genetic change) found through standard testing.
- You (or your legal guardian if you are under 18) must be willing to sign a consent form to participate.
- Your medical records must be available for the study team to review.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how different treatments work for people with advanced brain or spinal cord tumors that have come back. It helps doctors learn more about these tumors and how to better treat them.
This trial tests a drug called safusidenib in people with a slow-growing brain tumor (grade 2 glioma) that has a specific IDH1 gene mutation. The goal is to see if the drug can help control the tumor without needing chemotherapy or radiation right away.
This study looks at leftover tumor cells in people with a type of brain tumor called IDH-mutant glioma. Doctors want to learn how many tumor cells remain after treatment by testing tissue from a biopsy or surgery. This may help improve future care.
This study analyzes tissue and health-related biological data from people with glioblastoma to learn what’s happening in the tumor. The results may help improve future ways to understand and treat glioblastoma using advanced computer analysis.
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
This trial tests a new drug, HMPL-306, for people with a type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to see if the drug can shrink the tumor or slow its growth.
Hear when a new Diffuse Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.